Under the three batches, pharmaceutical companies cut sales costs into a general trend

"Pharmaceutical Network Market Analysis" October 27, Shanxi Province Medical Security Bureau announced that from November 1, all public medical institutions in Shanxi Province will fully implement the country's third batch of 55 kinds of drug centralized procurement results, so that the vast number of patients enjoy the drug belt procurement price reduction results.
the results of the third batch of centralized drug procurement in China, a total of 55 drugs 191 products were selected, the average price reduction of 53%, to a high of 95%.
55 varieties include commonly used therapeutic drugs such as hypertension, diabetes and antibiotics, as well as drugs for major diseases such as anti-cancer drugs.
is currently the third batch of national mining is entering the implementation phase of landing.
addition to Shanxi Province, according to incomplete statistics, so far, 26 provinces and cities have confirmed that the implementation of the national volume procurement results in November.
, Shanxi, Gansu, Jiangsu and other seven provinces are set to be formally implemented from November 1.
the normalization of drug collection has become a trend, drug price reduction is inevitable.
, China has successfully carried out three batches of national mining, involving a total of 112 drug varieties, the average price fell by 54%.
the State Health Insurance Administration estimates that the collection of 112 varieties, according to the agreed procurement volume, the annual cost of drugs will be reduced from 65.9 billion yuan to 12 billion yuan.
of 60% of the reimbursement rate, it will save patients $21.6 billion, as well as $32.3 billion for the health insurance fund.
through the drug price reduction, patients, especially those with chronic diseases will be greatly improved access to drugs, is expected to bring about an increase in drug sales.
For example, sales of the hepatitis B drug Entekawe increased from 68 million tablets to 207 million tablets after entering the "4 plus 7" collection, and sales of the high blood pressure drug ammonia chloride, Ebershatan and chlorosatan generally increased by about 1 times.
the normalization of collection, drug companies for the sale of the link of demand has also been greatly reduced, in the past with gold sales of drugs model is changing.
incomplete statistics, 59 enterprises in the same Huashun pharmaceutical manufacturing category have issued three-quarter 2020 reports.
, 42 companies had a 70 per cent decline in their sales expenses.
for example, the share of sales expenses in revenue decreased from 58.81 percent in the same period in 2019 to 46.81 percent this year, and total sales expenses decreased by 52.84 percent to 452 million yuan from 959 million yuan in the same period in 2019.
's sales expenses fell nearly 10 percent from 56.60 percent in the same period in 2019 to 46.69 percent this year.
the same period as the volume of procurement, Xinlitai's sales expenses also decreased from 1,166 million yuan in the same period in 2019 to about 450 million yuan in the third quarter of this year, a decrease of 38.60 percent year-on-year.
the impact of the outbreak and the reduction in sales costs corresponding to the band portion were the main factors.
For the reasons for the reduction in sales costs, Huahai Pharmaceuticals has mentioned that, mainly with the promotion of centralized national procurement, the company relies on the expansion of the alliance region election opportunities, product market coverage has been rapidly increased, thereby affecting the domestic agent sales increased significantly.
the third quarter of 2020, cutting sales costs is becoming more and more common.
, industry insiders said that drug companies to cut sales costs has become the trend.
with the normalization of collection and collection, the transformation of pharmaceutical sales model is imperative.
At the same time, the era of high gross margin of generic drugs will also pass, innovation has become the main theme of sustainable development of the pharmaceutical industry, in this context, pharmaceutical companies need to increase innovation and research and development efforts, promote the transformation and development of enterprises, adapt to the development trend of industrial transformation and upgrading, in order to go further.